Use Of Finasteride Reduces Alcohol Consumption.
Some men who use finasteride (Propecia) to balm Donnybrook baldness may also be drinking less alcohol, a new study suggests June 2013. Among the potency side effects of the hair-restoring drug are a reduced sex drive, concavity and suicidal thoughts. And it's men who have sexual side effects who also appear to want to guzzle less, the researchers report. "In men experiencing persistent sexual side junk despite stopping finasteride, two-thirds have noticed drinking less alcohol than before taking finasteride," said analysis author Dr Michael Irwig, an assistant professor of medicine at George Washington University School of Medicine and Health Sciences in Washington, DC.
Although it isn't obvious why the medication might have this effect, Irwig thinks the dull may alter the brain's chemistry. "Finasteride interferes with the brain's capability to make certain hormones called neurosteroids, which are likely linked to drinking alcohol. For younger men contemplating the use of finasteride for manly pattern hair loss, they should carefully up the modest cosmetic benefits of less hair loss versus some of the serious risks".
The report was published online June 13 in the almanac Alcoholism: Clinical and Experimental Research. "The biggest object to with this finding is that it is naturalistic rather than a controlled study so cause-and-effect is hard to establish," said James Garbutt, a professor of psychiatry at the University of North Carolina at Chapel Hill. "This is more of a cloud on the vista than a clear-cut effect".
If these findings are confirmed it suggests there may be a subgroup of people, it is possible that identifiable by their exposure of sexual side effects, who will experience reductions in alcohol consumption who was not involved with the study. "Based on the consumption levels reported in the paper, this denizens would be considered social drinkers and not delinquent drinkers".
Showing posts with label effects. Show all posts
Showing posts with label effects. Show all posts
Saturday 18 January 2020
Monday 23 December 2019
An Approved Vaccine To Treat Prostate Cancer Has Few Side Effects
An Approved Vaccine To Treat Prostate Cancer Has Few Side Effects.
The newly approved restorative prostate cancer vaccine, Provenge, is conservative and has few airs effects, a new study finds. In April, the US Food and Drug Administration approved the vaccine for use in men with advanced prostate cancer who had failed hormone therapy. "Provenge was approved based on both cover and clinical data," said prima donna researcher Dr Simon J Hall, bench of urology at Mount Sinai Medical Center in New York City.
This refuge data shows that there are very limited side effects. The superiority of the vaccine for patients with metastatic hormone-resistant prostate cancer is that it has fewer side stuff than chemotherapy, which is the only other treatment option for these patients. In addition, Provenge has improved survival over chemotherapy.
The mean survival time for men given Provenge is 4,5 months, although some patients saw their lives extended by two to three years. "This is a newly nearby treatment, with very limited standpoint effects, compared to anything else that a man would be considering in this state". Hall was to present the results on Monday at the American Urological Association annual convergence in San Francisco.
Data from four phase 3 trials, which included 904 men randomized to either Provenge or placebo, showed the vaccine extended survival, improved nobility of viability and had only mild side effects. In fact, more than 83 percent of the men who received Provenge were able to do appear as activities without any restrictions, the researchers noted.
The newly approved restorative prostate cancer vaccine, Provenge, is conservative and has few airs effects, a new study finds. In April, the US Food and Drug Administration approved the vaccine for use in men with advanced prostate cancer who had failed hormone therapy. "Provenge was approved based on both cover and clinical data," said prima donna researcher Dr Simon J Hall, bench of urology at Mount Sinai Medical Center in New York City.
This refuge data shows that there are very limited side effects. The superiority of the vaccine for patients with metastatic hormone-resistant prostate cancer is that it has fewer side stuff than chemotherapy, which is the only other treatment option for these patients. In addition, Provenge has improved survival over chemotherapy.
The mean survival time for men given Provenge is 4,5 months, although some patients saw their lives extended by two to three years. "This is a newly nearby treatment, with very limited standpoint effects, compared to anything else that a man would be considering in this state". Hall was to present the results on Monday at the American Urological Association annual convergence in San Francisco.
Data from four phase 3 trials, which included 904 men randomized to either Provenge or placebo, showed the vaccine extended survival, improved nobility of viability and had only mild side effects. In fact, more than 83 percent of the men who received Provenge were able to do appear as activities without any restrictions, the researchers noted.
Monday 22 January 2018
Doctors Recommend A New Treatment For Cancer
Doctors Recommend A New Treatment For Cancer.
The sedative Arimidex reduces the imperil of developing breast cancer by more than 50 percent among postmenopausal women at apex risk for the disease, according to a new study Dec 2013. The finding, scheduled for visual Thursday at the San Antonio Breast Cancer Symposium in Texas, adds look forward to that Arimidex (anastrozole) might be a valuable new preventive option for some women. The enquiry will also be published in the journal The Lancet.
So "Two other antihormone therapies, tamoxifen and raloxifene, are reach-me-down by some women to prevent breast cancer, but these drugs are not as effective and can have adverse side effects, which hold in check their use," study lead author Jack Cuzick said in a new release from the American Association for Cancer Research. "Hopefully, our findings will pre-eminence to an alternative prevention therapy with fewer ancillary effects for postmenopausal women at high risk for developing breast cancer," said Cuzick, aim of the Cancer Research UK Centre for Cancer Prevention and director of the Wolfson Institute of Preventive Medicine at Queen Mary University of London.
About 80 percent of US teat cancer patients have tumors with boisterous levels of hormone receptors, and these tumors are fueled by the hormone estrogen. Arimidex prevents the body from making estrogen and is therefore employed to treat postmenopausal women with hormone receptor-positive core cancer. The study included more than 3800 postmenopausal women at increased gamble for breast cancer due to having two or more blood relatives with breast cancer, having a mummy or sister who developed breast cancer before age 50, or having a spoil or sister who had breast cancer in both breasts.
The sedative Arimidex reduces the imperil of developing breast cancer by more than 50 percent among postmenopausal women at apex risk for the disease, according to a new study Dec 2013. The finding, scheduled for visual Thursday at the San Antonio Breast Cancer Symposium in Texas, adds look forward to that Arimidex (anastrozole) might be a valuable new preventive option for some women. The enquiry will also be published in the journal The Lancet.
So "Two other antihormone therapies, tamoxifen and raloxifene, are reach-me-down by some women to prevent breast cancer, but these drugs are not as effective and can have adverse side effects, which hold in check their use," study lead author Jack Cuzick said in a new release from the American Association for Cancer Research. "Hopefully, our findings will pre-eminence to an alternative prevention therapy with fewer ancillary effects for postmenopausal women at high risk for developing breast cancer," said Cuzick, aim of the Cancer Research UK Centre for Cancer Prevention and director of the Wolfson Institute of Preventive Medicine at Queen Mary University of London.
About 80 percent of US teat cancer patients have tumors with boisterous levels of hormone receptors, and these tumors are fueled by the hormone estrogen. Arimidex prevents the body from making estrogen and is therefore employed to treat postmenopausal women with hormone receptor-positive core cancer. The study included more than 3800 postmenopausal women at increased gamble for breast cancer due to having two or more blood relatives with breast cancer, having a mummy or sister who developed breast cancer before age 50, or having a spoil or sister who had breast cancer in both breasts.
Friday 13 May 2016
Marijuana Affects The Index IQ
Marijuana Affects The Index IQ.
A unfamiliar analysis challenges former research that suggested teens put their long-term brainpower in danger when they smoke marijuana heavily. Instead, the study indicated that the earlier findings could have been thrown off by another factor - the effect of inadequacy on IQ. The author of the new analysis, Ole Rogeberg, cautioned that his theory may not hold much water. "Or, it may say out that it explains a lot," said Rogeberg, a research economist at the Ragnar Frisch Center for Economic Research in Oslo, Norway.
The authors of the inaugural study responded to a solicit for comment with a joint statement saying they stand by their findings. "While Dr Rogeberg's ideas are interesting, they are not supported by our data," wrote researchers Terrie Moffitt, Avshalom Caspi and Madeline Meier. Moffitt and Caspi are nature professors at Duke University, while Meier is a postdoctoral allied there.
Their study, published in August in the Proceedings of the National Academy of Sciences, attracted media acclaim because it suggested that smoking spare tyre has more than short-term effects on how people think. Based on an examination of mental tests given to more than 1000 New Zealanders when they were 13 and 38, the Duke researchers found that those who heavily second-hand marijuana as teens lost an average of eight IQ points over that time period.
It didn't seem to puzzle if the teens later cut back on smoking pot or stopped using it entirely. In the pithy term, people who use marijuana have memory problems and trouble focusing, research has shown. So, why wouldn't users have problems for years?
A unfamiliar analysis challenges former research that suggested teens put their long-term brainpower in danger when they smoke marijuana heavily. Instead, the study indicated that the earlier findings could have been thrown off by another factor - the effect of inadequacy on IQ. The author of the new analysis, Ole Rogeberg, cautioned that his theory may not hold much water. "Or, it may say out that it explains a lot," said Rogeberg, a research economist at the Ragnar Frisch Center for Economic Research in Oslo, Norway.
The authors of the inaugural study responded to a solicit for comment with a joint statement saying they stand by their findings. "While Dr Rogeberg's ideas are interesting, they are not supported by our data," wrote researchers Terrie Moffitt, Avshalom Caspi and Madeline Meier. Moffitt and Caspi are nature professors at Duke University, while Meier is a postdoctoral allied there.
Their study, published in August in the Proceedings of the National Academy of Sciences, attracted media acclaim because it suggested that smoking spare tyre has more than short-term effects on how people think. Based on an examination of mental tests given to more than 1000 New Zealanders when they were 13 and 38, the Duke researchers found that those who heavily second-hand marijuana as teens lost an average of eight IQ points over that time period.
It didn't seem to puzzle if the teens later cut back on smoking pot or stopped using it entirely. In the pithy term, people who use marijuana have memory problems and trouble focusing, research has shown. So, why wouldn't users have problems for years?
Sunday 29 September 2013
The Use Of Nicotinic Acid In The Treatment Of Heart Disease
The Use Of Nicotinic Acid In The Treatment Of Heart Disease.
Combining the vitamin niacin with a cholesterol-lowering statin dull appears to suggest patients no gain and may also lengthen side effects, a new library indicates. It's a disappointing result from the largest-ever study of niacin for spunk patients, which involved almost 26000 people effects. In the study, patients who added the B-vitamin to the statin hypnotic Zocor saying no added benefit in terms of reductions in heart-related death, non-fatal pluck attack, stroke, or the need for angioplasty or ignore surgeries.
The study also found that people taking niacin had more incidents of bleeding and (or) infections than those who were intriguing an inactive placebo, according to a troupe reporting Saturday at the annual meeting of the American College of Cardiology, in San Francisco. "We are defeated that these results did not show benefits for our patients," exploration lead author Jane Armitage, a professor at the University of Oxford in England, said in a assembly telecast release. "Niacin has been used for many years in the belief that it would help patients and taboo heart attacks and stroke, but we now know that its adverse affectation effects outweigh the benefits when used with current treatments".
Niacin has hanker been used to boost levels of "good" HDL cholesterol and curtailment levels of "bad" LDL cholesterol and triglycerides (fats) in the blood in common people at risk for heart disease and stroke. However, niacin also causes a numeral of side effects, including flushing of the skin. A medicine called laropiprant can lose weight the incidence of flushing in people taking niacin. This unknown study included patients with narrowing of the arteries.
They received either 2 grams of extended-release niacin benefit 40 milligrams of laropiprant or analogous placebos. All of the patients also took Zocor (simvastatin). The patients from China, the United Kingdom and Scandinavia were followed for an mediocre of almost four years.
Combining the vitamin niacin with a cholesterol-lowering statin dull appears to suggest patients no gain and may also lengthen side effects, a new library indicates. It's a disappointing result from the largest-ever study of niacin for spunk patients, which involved almost 26000 people effects. In the study, patients who added the B-vitamin to the statin hypnotic Zocor saying no added benefit in terms of reductions in heart-related death, non-fatal pluck attack, stroke, or the need for angioplasty or ignore surgeries.
The study also found that people taking niacin had more incidents of bleeding and (or) infections than those who were intriguing an inactive placebo, according to a troupe reporting Saturday at the annual meeting of the American College of Cardiology, in San Francisco. "We are defeated that these results did not show benefits for our patients," exploration lead author Jane Armitage, a professor at the University of Oxford in England, said in a assembly telecast release. "Niacin has been used for many years in the belief that it would help patients and taboo heart attacks and stroke, but we now know that its adverse affectation effects outweigh the benefits when used with current treatments".
Niacin has hanker been used to boost levels of "good" HDL cholesterol and curtailment levels of "bad" LDL cholesterol and triglycerides (fats) in the blood in common people at risk for heart disease and stroke. However, niacin also causes a numeral of side effects, including flushing of the skin. A medicine called laropiprant can lose weight the incidence of flushing in people taking niacin. This unknown study included patients with narrowing of the arteries.
They received either 2 grams of extended-release niacin benefit 40 milligrams of laropiprant or analogous placebos. All of the patients also took Zocor (simvastatin). The patients from China, the United Kingdom and Scandinavia were followed for an mediocre of almost four years.
Subscribe to:
Posts (Atom)